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 Liposomal-lupane is able to decrease
the growth/survival of Leishmania
amastigotes.
 The formulation could inhibit the
size of paw lesions in BALB/c-infected
mice.
 Liposomes induce IL-12 and decrease
IL-10 levels for the resolution of
infection.g r a p h i c a l a b s t r a c t
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Macrophagesa b s t r a c t
Leishmania amazonensis causes human diseases that range from self-healing to diffusion cutaneous
lesions. The chemotherapy of leishmaniasis requires long-term treatment and has been based on the
use of pentavalent antimonials. Liposomes have been used as antileishmanial drug carries and have adju-
vant activity in vaccines against several microorganisms, representing an important option to the devel-
opment of new therapeutics for the disease. In this study, we developed a liposomal formulation
containing lupane [3b,6b,16b-trihydroxylup-20(29)-ene], isolated from fruits of Combretum leprosum
with pharmacological properties as antinociceptive, anti-inﬂammatory, antiulcerogenic and antileishma-
nial activities. The aim of the present study was to evaluate the efﬁcacy of liposomal-lupane in L. ama-
zonensis-infection model. Liposomes were prepared by the extrusion method with DPPC, DPPS and
cholesterol at 5:1:4 weight ratio. The lupane (2 mg/mL) was added to the lipid mixture, solubilized in
chloroform and dried under nitrogen ﬂow. The activity of liposomal-lupane was conducted in vitro with
mouse peritoneal infected macrophages. Furthermore, mice were infected in the right hind footpad with
105 stationary growth phase of L. amazonensis promastigotes. After 6 weeks, animals were treated with
liposomal-lupane for 15 days by intraperitoneal injection. The evolution of disease was monitored
weekly by measuring footpad thickness with a caliper. Three days after the treatment, peritoneal macro-
phages were collected, plated and production of the cytokines IL-10 and IL-12 was evaluated in superna-
tants of the cultures after 24 h. The results indicate that the liposomal system containing lupane achieved
here is a promising tool to confer antileishmanial activity to infected macrophages.
 2013 Elsevier Inc. All rights reserved.1. Introduction
Leishmaniases are diseases caused by protozoa of the genus
Leishmania and, clinically, may present as visceral, cutaneous or
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tant zoonotic disease that occurs in theOldWorld and the Americas,
characterizing itself as a serious public health problem inpoor coun-
tries and apriority of the endemics of theWorldHealthOrganization
(WHO). The American Cutaneous Leishmaniasis (ACL) can be pres-
ent in three forms: cutaneous, mucocutaneous/cutaneous leish-
maniasis and diffuse. Cutaneous leishmaniasis, the most common
form, is characterized by skin lesions, ulcerated or not, however
limited. The mucocutaneous leishmaniasis produces destructive le-
sions in the mucous membranes of the nose, mouth and pharynx.
Typical lesions arise that involve the skin and mucous membranes
and can occur metastasized to other parts of the body distant from
the site of the bite. In Brazil, it is caused by Leishmania (Viannia)
braziliensis, Leishmania (Leishmania) amazonensis and Leishmania
(Viannia) guyanensis. The diffuse cutaneous form is a rare and severe
clinical form, which occurs in patients with deﬁcient cellular im-
mune response and is associated with infection with L. amazonensis
(Piscopo and Mallia, 2006).
Over the past 90 years, the pentavalent antimony (Sb +5) is
the drug of ﬁrst choice recommended for the treatment of leish-
maniasis (Rath et al., 2003). The high toxicity of this and other
drugs, with reports of sudden death, is a limiting factor for their
therapeutic use. Among the major adverse effects or side effects,
the most common adverse reactions are pain, induration and
sterile abscess at the site of application, as well as nausea, vom-
iting, dizziness, myalgia, headache, hypotension, hypoglycemia
and hyperglycemia (Lima et al., 2007). Many compounds isolated
from plants, such as chalcones, alkaloids, lignans, neolignans and
triterpenes have been described as compounds with promising
activity against protozoa (Dzubak et al., 2006). Regarding these
phytocompounds, the triterpenesrepresent an expansion promis-
ing biologically active natural compounds whose potential is
only partially exploited by the pharmaceutical industry (Dzubak
et al., 2006). It has been reported its anti-inﬂammatory, analge-
sic, antimicrobial, antimycotic and immunomodulatory activities.
The disadvantage of using triterpenoids, in fact, is the toxicity
associated with its hemolytic and cytostatic properties (Dzubak
et al., 2006). The triterpenes exhibit a wide structural diversity
and can be classiﬁed into tetracyclic, pentacyclic and acyclic
(Xu et al., 2004).
The lupane used in this study was isolated from Combretum
leprosum, a kind honey scandent shrub with two to three feet tall,
found in the states of Northeast and also in the states of Mato Gros-
so and Mato Grosso do Sul, Brazil (Facundo et al., 1993). The
3b,6b,16b-triidroxilup-20(29)-ene, a class of lupane triterpene, iso-
lated from the ﬂowers of C. leprosum showed antinociceptive activ-
ity and leishmanicidal activity against promastigotes forms of
L. amazonensis (Teles et al., 2011). This lupane was able to reduce
the infection rate and the amount of intracellular amastigotes in
peritoneal macrophages.
Liposomes are microscopic spherical vesicles composed of
phospholipids and natural or synthetic aggregate bilayer. They
are comprised of one or more concentric lipid bilayers sepa-
rated by aqueous layers and comprising an internal aqueous
compartment. Since they are biodegradable, non-immunogenic
and biocompatible, the structures are versatile, with features
to reduce toxicity of substances. Also, they allow changes in
their lipid composition, which address the liposome to speciﬁc
cellular targets (Kalyankar et al., 2010). These drug carrier sys-
tems have been extensively studied and applied in the pharma-
ceutical, cosmetic, food, veterinary and clinical diagnosis. They
represent a vesicular better therapy for certain diseases, such
as for the treatment of leishmaniasis with liposomal amphoter-
icin B, controlling the release of drug by increasing their
pharmacokinetics and tissue reducing toxicity (Nicoletti et al.,
2009).The aim of the present study was to evaluate the efﬁcacy of
liposomal-lupane in both in vitro and in vivo L. amazonensis-infec-
tion models.2. Materials and methods
2.1. Preparation of liposomes
Liposomes were prepared as described (Tempone et al., 2004)
with modiﬁcations. The lipids used were dipalmitoylphosphatidyl-
choline (DPPC), dipalmitoylphosphatidylserine (DPPS) and choles-
terol (all reagents from Sigma–Aldrich) in the ratio 5:1:4. They
were dissolved in a glass tube with 2 mL chloroform/methanol
(Dinamica, São Paulo, Brazil) (1:1, v/v). Then, the tube was vor-
texed and subjected to ultrasonic bath repeatedly until the lipids
dissolved completely. After the dissolution of lipids, a solution of
chloroform/methanol was removed by evaporation, yielding a ﬁlm
of lipids on the inner wall of the tube. This ﬁlm was vacuum dried
in a desiccator for about 18 h and subsequently lipids were resus-
pended in 2 mL of 5 mM Tris–HCl, pH 7.5. The solution was then
incubated for 1 h at 60 C with agitation every 10 min. The emul-
sion was subjected to an extruder (LiposoFastTM, Avestin, Ottawa,
Canada) with a polycarbonate membrane with pores of 100–
200 nm by 20 times to produce a population of liposomes of uni-
form size. For the preparation of liposomal-lupane, 2 mg of lupane
triterpene were added to the lipids’ solution, at the beginning of
the preparation. The determination of the size of the liposomes
was performed by dynamic light scattering using a Beckman Coul-
ter Submicron Particle Analyzer Model (N5). The surface charge of
the liposomes before and after permeation proﬁle and the incorpo-
ration of lupane was evaluated from measurements of Zeta poten-
tial (f). This represents the residual negative charge on the particle
surface. The samples were added to the cuvette containing the
electrodes with a capacity of about 1 mL.
2.2. Animals
BALB/c mice, male, 8–10 weeks old, weighing 20–28 g, were ob-
tained from the facility of the Instituto de Pesquisas em Patologias
Tropicais (Ipepatro), Brazil. The animals were kept under standard-
ized animal house conditions. The experiments were performed in
accordance with standards established by the Ethics Committee on
Animal Use upon approval of the research project under No. 2008/
5.
2.3. In vitro infection of peritoneal macrophages
BALB/c mice were inoculated i.p. with 2 mL of 3% thioglycolate
(Sigma–Aldrich) (8). After 4 days, the animals were euthanized by
cervical dislocation and 5 ml of cold RPMI were injected into the
peritoneal cavity and then recovered with a syringe. The peritoneal
ﬂuid was centrifuged at 250g for 10 min at 4 C and the superna-
tant discarded. Then, the pellet was resuspended in 5 mL of RPMI
medium and the cells obtained were counted in a Neubauer cham-
ber. Macrophages (5  105/well) were plated in a 24 well plate
containing sterile coverslips and incubated at 37 C with humidi-
ﬁed atmosphere containing 5% CO2. Macrophages after 4 h incuba-
tion were washed twice with RPMI medium and then infected with
promastigotes of L. amazonensis parasites (IFLA/BR/67/PH8), in the
proportion of 5:1 macrophage. The infected cells were incubated
‘‘overnight’’ at 34 C with a humidiﬁed atmosphere containing 5%
CO2. After this period, the wells were washed with RPMI and again
treated with control liposomes and liposomal lupane (6 lg/mL).
Pentamidine was used as reference drug. Infected cells were used
untreated as a positive control of infection. The infected cultures
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these periods, the culture supernatants were collected and frozen
for later cytokines’ quantiﬁcation. The infection rate and the num-
ber of intracellular parasites were evaluated by counting 100 mac-
rophages in optical microscope – an increase of 1000. Slides were
stained by May Grünwald-Giemsa (Giaimis et al., 1992). The phag-
ocytic index (Ranzani-Paiva et al., 2008) was determined using the
formula: % of infected macrophages  total of Leishmania
amastigotes.2.4. In vivo infection and treatment of BALB/c mice
BALB/c mice were inoculated in the right hind paw with 105
promastigotes of L. amazonensis in PBS. After 6 weeks the treat-
ment was started and the mice were separated, according to the
treatment received in four groups. During 15 consecutive days
each group received i.p. 100 lL of control and liposomal lupane
(6 mg/kg). Pentamidine (4 mg/kg) was used i.p. as reference drug
to treat the infection. As indication for treatment by the Brazilian
Ministry of Health, Pentamidine was administered in alternated
days. The progression of the lesion was monitored two times per
week by measuring the size of the lesions with a pachymeter.
The evolution of the disease in infected animals and the control
group was evaluated weekly after initiation of treatment, for a per-
iod of 3 weeks by comparison of lesion size paw infected with the
measurement of the uninfected contralateral paw. The results were
expressed as the mean difference of the size of contralateral in-
fected and uninfected paws. After 5 days of the end of the treat-
ment, the animals were euthanized and peritoneal macrophages
were collected, according to Section 2.3. The macrophage cultures
were incubated at 37 C for 24, 48, 72 and 96 h. After each period,
the supernatants were collected and stored at20 C for later cyto-
kines’ quantiﬁcation.2.5. Ex vivo determination of cytokines’ production
BALB/c mice were infected according previously. After 6 weeks
of infection, each group was treated for 15 days. On the 20th day,
the animals were euthanized by cervical dislocation and ice-cold
PBS was injected into the peritoneal cavity of each mouse to collect
the macrophages. Then, 1  105 cells were incubated at 37 C in
periods of 48 and 96 h. After each period, the supernatants were
collected and stored at 20 C for cytokine assay.
The cytokines IL-10 and IL-12 were quantitated in the superna-
tants of cultures of peritoneal macrophages collected from the as-
say previously described (Section 2.4). For each cytokine,
measurements were made using the enzyme immunoassay cap-
ture ELISA. For this we used the DuoSet kit, R&D Systems and BD
Pharmingen according to the manufacturer’s instructions.Table 1
Determination of the size and zeta potential of the liposomes.
Formulations Vesicle size (nm) Zeta potential (mV)
Control liposome 214.4 ± 0.12 52.5
Liposomal-lupane 143.3 ± 0.27 51.1
Size (nm) and Zeta potential (f) of control liposomes and those containing lupane.
The measurements were performed with samples diluted in the range of four times,
using HEPES buffer as a dispersion medium, at 25 C. Values were obtained from
two different batches.2.6. Histopathologic analysis of the paw lesions in mice infected with
L. amazonensis
Mice paws were collected and ﬁxed in 10% formalin for a period
of 24 h. After this, the paws were stored in PBS formalin (10% v/v)
until histological processing. Subsequently, they were decalciﬁed
in EDTA solution at 10% in PBS for 4 days at a temperature of
4 C. The samples were then subjected to parafﬁn embedding pro-
cess for sagittal section (5 lm). The sections were dehydrated and
diaphanized using increasing concentrations of alcohols and xylols,
stained with hematoxylin and eosin and covered with coverslips
for further analysis in light microscopy at 100 magniﬁcation to
assess the standard and intensity of tissue changes and cellular
inﬁltration.2.7. Statistical analysis
Data obtained represent the mean and standard deviation of
samples from two or three independent assays. One-way ANOVA
test (Tuckey post-test) was performed using GraphPad Prism 5.0
software (GraphPad Software Inc., La Jolla, CA) and analysis of var-
iance to determine the level of signiﬁcance set at p < 0.05.3. Results
3.1. Characterization of the liposomes
The homogeneous generation and also the uniformity of lipo-
somes formulations during the extrusion method were assessed
using a particle size analyzer. Analyses by dynamic light scattering
showed homogeneous population of both control and lupane lipo-
somes. Table 1 shows sizes around 214.4 ± 0.12 nm and
146.3 ± 0.27 nm for control and liposomal-lupane, respectively.
According to the data obtained, no signiﬁcant difference in Zeta po-
tential between control (52.5 mV) and lupane (51.1 mV) lipo-
somes was achieved. The feasibility of liposomes containing
lupane was determined by MTT assay using peritoneal macro-
phages from BALB/c mice after 24, 48 and 72 h incubation. Macro-
phages treated with liposomal lupane showed about 60% viability
at high concentrations (above 100 lg/mL) (data not shown).3.2. Liposomal-lupane decreases the growth/survival of the parasite
inside the macrophages
Fig. 1(A) and (B) shows that, after 48 and 72 h incubation of in-
fected macrophages with liposomal-lupane, a signiﬁcant reduction
of parasite survival was achieved (55.5% and 61.7%, respectively)
compared to the control group. Pentamidine, as expected, pre-
sented greater signiﬁcant reduction of 80.1% compared to un-
treated control group. Also, after 72 h, amastigote-infected
macrophages incubated with liposomal-lupane presented signiﬁ-
cant reduction of the intracellular parasite survival compared with
the control liposomes.
When the percentage of infected macrophages was correlated
with total of Leishmania amastigotes, the phagocytic index was
achieved. Fig. 1(C) and (D) presents these results and they repro-
duce the same phenomenon described above.3.3. Treatment with liposomal-lupane decreases paw lesions size in
L. amazonensis-infected mice
In order to evaluate the leishmanicidal effect of liposomal-lu-
pane in animal model of cutaneous leishmaniasis, BALB/c mice
were infected with 105 promastigotes of L. amazonensis. After
6 weeks, animals were treated for two consecutive days with con-
trol liposomes, liposomal-lupane (6 mg/kg) and Pentamidine
(4 mg/kg) by i.p. route. The groups were treated every other day




























































































Fig. 1. Analysis of growth/survival of the parasite and phagocytic index in the macrophages after incubation with liposomes. Peritoneal macrophages were infected with
promastigotes of L. amazonensis in stationary growth phase at a ratio of 5 parasites per cell. The peritoneal macrophages were in vitro infected and incubated 48 h (A) and 72 h
(B) with 6 lg/mL of control liposomes or liposomal-lupane; Pentamidine was used as control. Phagocytic index of peritoneal macrophages after incubation with liposomes
was achieved for 48 h (C) and 72 h (D). Each bar represents the mean ± S.D. of three independent experiments performed in triplicate. (*) (p < 0.05) Compared to control, (–)
















340 N.B. Barros et al. / Experimental Parasitology 135 (2013) 337–343Fig. 2 shows the progression of the paw lesions, and also the
proﬁle of a lesion in mice without any treatment. It could be noted
that on day 21, animals from control liposome, liposomal-lupane
and Pentamidine groups showed a decrease in lesion size com-
pared to the untreated control group. Mice that received liposomes
containing lupane presented a statistically signiﬁcant reduction in
the lesion size by approximately 33% compared with untreated in-










Fig. 2. Effect of the treatment with liposomal-lupane on L. amazonensis infected-
mice. BALB/c mice were inoculated with promastigotes of L. amazonensis (1  105)
and after 6 weeks were treated intraperitoneally for 15 days with 100 lL of
liposome or liposomal-lupane (6 mg/kg) and Pentamidine (4 mg/kg). The size of the
paw lesion was monitored with the aid of a slide caliper in two steps weekly over
21 days. The data represent the mean ± S.D. obtained for the lesions in two
independent experiments, ﬁve animals per group. (*) Indicates a statistically
signiﬁcant difference from the 15th day of treatment comparing liposome and
liposomal-lupane groups with control (p < 0.05).3.4. Liposomal-lupane increases TH1 protective cytokines ex vivo
Fig. 3 shows the results from cytokines’ production by macro-
phages of infected and treated animals, as described (Section
2.4). Regarding IL-12 levels (Fig. 3(A)), ex vivo infected macro-
phages treated with both control liposome and liposomal-lupane
showed a signiﬁcant increase in the production of this cytokine
when compared to the uninfected (control) and infected (un-
treated) macrophages. IL-10 levels (Fig. 3(B)) from infected macro-
phages treated with liposomal-lupane revealed a signiﬁcant
reduction in the levels of this cytokine compared to infected mac-
rophages and also to those incubated with control liposomes only.
As a reference drug, Pentamidine was able to decrease the levels of
both cytokines by infected macrophages.
Fig. 3. Ex vivo production of the cytokines IL-12 and IL-10 in the supernatants of L. amazonensis-infected macrophages. Evaluation of ex vivo production of cytokines by
peritoneal macrophages from BALB/c mice infected with L. amazonensis and treated with liposomes. (A) IL-12 after 48 h of incubation and (B) IL-10 production in the
supernatants of macrophages after 96 h incubation. Cytokine concentrations were determined by ELISA. Each point represents the mean of cytokine production (pg/mL) ±S.D.
(*) (p < 0.05) and (**) (p < 0.01) indicate a statistically signiﬁcant difference comparing liposomes and liposomal-lupane with control infected group; (–) (p < 0.05) liposomal-
lupane compared with liposomes.
Fig. 4. Histopathologic analysis of the paw lesion in mice infected with L. amazonensis. (A) Control infected animals and (B) animals treated with liposomal-lupane. Arrows
indicate amastigote nests. Magniﬁcations 100.
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macrophages
Histopathologic sections from Fig. 4 revealed that there are dif-
ferences between the paw lesions from infected mice treated and
not with liposomal-lupane. Numerous macrophage cytoplasms,
large, clear and vacuolated were found in the dermis of the control
group of mice infected with L. amazonensis (Fig. 4(A)). Macro-
phages were heavily infected, as indicated by the presence of a
large number of amastigotes inside the vacuoles (arrows). In con-
trast, infected mice treated with the liposomal-lupane despite a
vacuolization with destruction of the dermis showing no apparent
parasites (Fig. 4(B)).4. Discussion
Compounds encapsulated in liposomes become a viable alterna-
tive to diminish side effects unchained by classical drugs used to
treat leishmaniasis, making their easier handling to be continued
by the patient. The liposomal carrier vesicles have been important
for the treatment of various diseases, including leishmaniasis, dueto the fact that the encapsulated molecules can be retained intra-
cellularly and directed to speciﬁc targets, reducing toxicity and
preventing their degradation.
Regarding this drug delivery approach, liposomes have been
used in experimental therapeutics as carriers for drugs (Kalyankar
et al., 2010). Their layer composition has an important effect on its
interaction with tissues and might be critical for the targeting to
speciﬁc antigen presenting cells. Studies have demonstrated that
liposomes containing DPPS enhances the production of IFN-c, a
TH1-driving cytokine (Yotsumoto et al., 2007). Furthermore, DPPS
liposomes entrapping pentavalent antimony have been shown to
be captured by macrophages via scavenger receptors (Tempone
et al., 2005). The tendency of liposomes to be captured by the
mononuclear phagocytic system may be an advantage in treating
a variety of intracellular infectious diseases. The increase of 200–
700 times in the efﬁcacy using liposomal pentavalent antimonials
was observed in the treatment of visceral leishmaniasis in mice in-
fected with Leishmania donovani. This fact can be attributed to the
capture of liposomes by the organs and cells (tissue macrophages),
which are located the parasites (Batista et al., 2007). Liposomes are
the most drug delivery systems studied for leishmaniasis when
compared to any other parasitic disease mainly due to the fact that
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amastigotes forms, and also responsible for the removal of the lip-
osomes in vivo.
In the context of alternative antileishmanial therapies, many
compounds isolated from plants, such as chalcones, alkaloids, lign-
ans, neolignans and triterpenes have been described as compounds
with promising activity against protozoa (Izumi et al., 2008).
Regarding triterpenes, it has been reported its anti-inﬂammatory,
analgesic, antimicrobial, antimycotic and immunomodulatory
activities. The disadvantage of using triterpenoids, in fact, is the
toxicity associated with its hemolytic and cytostatic properties
(Dzubak et al., 2006).
Recently, it was showed that the viability of peritoneal macro-
phages from BALB/c mice decreased by 50% when they were incu-
bated with the lupane solution (concentration at 10 lg/mL or
above) (Teles et al., 2011). However, the effect of encapsulated lu-
pane on macrophage activation has not yet been determined. In or-
der to be considered ideal for therapeutic use, liposomes should
provide molecule protection against metabolic processes and adja-
cent tissues, and also increase drug uptake by target cells (Kalyan-
kar et al., 2010).
In this study, the size distribution of the liposomal vesicles
constructed showed that both control and those liposomes con-
taining lupane had a size greater than 100 nm, and also pre-
sented homogeneous populations of the vesicles formed.
Determination of Zeta-potential can also be useful in elucidating
the relationship of the charges of encapsulated drugs with the
liposomal vesicles (Alonso et al., 1991). When analyzed, both
formulations presented results around 52.0 mV. The Zeta-po-
tential reﬂects the surface potential of particles, which is inﬂu-
enced by changes in the interface with the dispersing medium,
due to decoupling of functional groups on the particle surface
or adsorption of ionic species present in the aqueous dispersion
(Mosqueira et al., 2000). The results showed that when the lu-
pane was added to the vesicles to form liposomal structure,
the negatively charged surface was maintained during the pro-
cess and no further ion change was produced.
Teles et al. (2011) showed that the triterpene lupane, as a free
non-encapsulated compound at a concentration of 5 mg/mL, pre-
sented a potent inhibitory activity on L. amazonensis promastigotes
proliferation (IC50 = 3.3 mg/mL). Based on this toxic activity, for
the ﬁrst time we have proposed this study regarding the effect of
lupane encapsulated into liposomes on the survival/growth of
intracellular L. amazonensis amastigotes in order to correlate the
antileishmanial activity elicited by lupane (free in solution or
encapsulated) on both promastigote and amastigote forms. The
liposomal-lupane reduced the amount of intracellular amastigotes
and also the phagocytic index elicited by macrophages. These data
therefore suggest that the uptaked liposomal-lupane affects the
parasitic status of amastigotes inside macrophages, demonstrating
also its leishmanicidal activity indirectly. Moreover, the results
from the treatment of L. amazonensis-infected mice with liposomes
showed that there was a decrease in the size of paw lesions (33%),
monitored over a period of 21 days, when compared to infected
and untreated groups. In this context of parasite infection inside
the macrophages and paw lesions it can be pointed out the study
with more than 30 cases of ACL in the Amazon region, where the
main ﬁnding was the presence of large amounts of vacuolated
macrophages, richly parasitized, also with lymphocytic cellular
inﬁltrate (Silveira et al., 2005). The main histological characteristic
of the infection by L. amazonensis is the accumulation observed in
the dermis with numerous macrophages containing a large vacuole
in the cytoplasm ﬁlled with amastigotes. With this regard, in this
study, liposomes could release lupane inside the infected macro-
phages and provide clear decrease in the number of amastigote
nests.Taking together, our in vitro and in vivo results show that encap-
sulated lupane can act as an efﬁcient antileishmanial therapeutic
for controlling the parasite infection and also its intracellular per-
manence inside the macrophages.
The control of leishmaniasis in initial steps of the infection and
during chemotherapy is dependent on macrophage activation
mediated by T cells. The process of signaling between macro-
phages, lymphocytes and dendritic cells is accomplished primarily
through the release of cytokines, which stimulate the production of
multiple costimulatory molecules in the membrane surface and
toxic reactive molecules against Leishmania amastigotes inside
the macrophages. The activity of the parasite subversive process
can take place by inhibiting production of IL-12, which is necessary
for antileishmanial activity of macrophages (Kedzierski et al.,
2009). The production of this cytokine by macrophages features a
TH1 response that is associated with resistance to infection, since
this type of response is represented by cells producing IL-12,
TNF-a and IFN-y cytokines (Murray et al., 2002).
The results from ex vivo experiments showed that the liposomes
containing lupane were able to stimulate an increase in IL-12 pro-
duction by L. amazonensis-infected macrophages and also, on the
other hand, to reduce the production of IL-10. Both in in vitro (data
not shown) and ex vivo experiments, it could be observed a de-
crease of this cytokine production by macrophages treated with
liposomal-lupane. It has been well documented the role of IL-10
for contributing to disease progression in leishmaniasis, disabling
TH1 responses (Trinchieri et al., 2003; Saha et al., 2006) and acting
simultaneously with IL-4 in the deactivation of infected macro-
phages, making them susceptible to the action of Leishmania (Mur-
ray et al., 2002).
In light of this context and other features in combination using
liposomes to treat intracellular infections, our results can contrib-
ute to the advancement in the search for new therapeutic drugs
and formulations, which may improve antimicrobial host defenses
against the leishmaniasis, a disease that represents major public
health problem, especially in underdeveloped countries.Acknowledgments
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